Evaluating the Effects of CDK Inhibitors in Ischemia–Reperfusion Injury Models

  • Tatiana GuevaraEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1336)


CDK inhibitors have been used to induce protection in various experimental models. Kidney ischemia–reperfusion (I/R) is a form of acute kidney injury resulting in a cascade of cellular events prompting rapid cellular damage and suppression of kidney function. I/R injury, an inevitable impairment during renal transplant surgery, remains one of the major causes of acute kidney injury and represents the most prominent factor leading to delayed graft function after transplantation. Understanding the molecular events responsible for tubule damage and recovery would help to develop new strategies for organ preservation. This chapter describes procedures to study the effect of CDK inhibitors in the cellular I/R model developed from an epithelial cell line deriving from pig kidney proximal tubule cells (LLC–PK1). We briefly describe methods for determining the protective effect of CDK inhibitors such as activation of caspase 3/7, western blot analysis, gene silencing, and immunoprecipitation.

Key words

CDK inhibitors Kidney injury Ischemia–reperfusion Renal preservation 


  1. 1.
    Orzaez M, Guevara T, Sancho M, Perez-Paya E (2012) Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. Cell Death Dis 3:e415PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Iyirhiaro GO, Brust TB, Rashidian J, Galehdar Z, Osman A, Phillips M, Slack RS, Macvicar BA, Park DS (2008) Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia. J Neurochem 105(3):703–713PubMedCrossRefGoogle Scholar
  3. 3.
    Hilton GD, Stoica BA, Byrnes KR, Faden AI (2008) Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J Cereb Blood Flow Metab 28(11):1845–1859PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Menn B, Bach S, Blevins TL, Campbell M, Meijer L, Timsit S (2010) Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One 5(8):e12117PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Guevara T, Sancho M, Perez-Paya E, Orzaez M (2014) Role of CDK5/cyclin complexes in ischemia-induced death and survival of renal tubular cells. Cell Cycle 13(10):1617–1626PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Bagshaw SM, Mortis G, Godinez-Luna T, Doig CJ, Laupland KB (2006) Renal recovery after severe acute renal failure. Int J Artif Organs 29(11):1023–1030PubMedGoogle Scholar
  7. 7.
    Kosieradzki M, Rowinski W (2008) Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 40(10):3279–3288PubMedCrossRefGoogle Scholar
  8. 8.
    Singh D, Chander V, Chopra K (2005) Cyclosporine protects against ischemia/reperfusion injury in rat kidneys. Toxicology 207(3):339–347PubMedCrossRefGoogle Scholar
  9. 9.
    Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor JL (2007) Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine. Transplantation 84(2):187–195PubMedCrossRefGoogle Scholar
  10. 10.
    Aydemir A, Abbasoglu O, Topaloglu S, Ertoy D, Ayhan A, Kilinc K, Karabulut E, Sayek I (2002) Protective effect of roscovitine on renal ischemia-reperfusion injury. Transplant Proc 34(6):2027–2028PubMedCrossRefGoogle Scholar
  11. 11.
    Osuga H, Osuga S, Wang F, Fetni R, Hogan MJ, Slack RS, Hakim AM, Ikeda JE, Park DS (2000) Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A 97(18):10254–10259PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Canela N, Orzaez M, Fucho R, Mateo F, Gutierrez R, Pineda-Lucena A, Bachs O, Perez-Paya E (2006) Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. J Biol Chem 281(47):35942–35953PubMedCrossRefGoogle Scholar
  13. 13.
    Hotter G, Palacios L, Sola A (2004) Low O2 and high CO2 in LLC-PK1 cells culture mimics renal ischemia-induced apoptosis. Lab Invest 84(2):213–220PubMedCrossRefGoogle Scholar
  14. 14.
    Taniguchi Y, Pippin JW, Hagmann H, Krofft RD, Chang AM, Zhang J, Terada Y, Brinkkoetter P, Shankland SJ (2012) Both cyclin I and p35 are required for maximal survival benefit of cyclin-dependent kinase 5 in kidney podocytes. Am J Physiol Renal Physiol 302(9):F1161–F1171PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Brinkkoetter PT, Olivier P, Wu JS, Henderson S, Krofft RD, Pippin JW, Hockenbery D, Roberts JM, Shankland SJ (2009) Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J Clin Invest 119:3089PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Brinkkoetter PT, Pippin JW, Shankland SJ (2010) Cyclin I-Cdk5 governs survival in post-mitotic cells. Cell Cycle 9(9):1729–1731PubMedCrossRefGoogle Scholar
  17. 17.
    Fearnhead HO (2001) Cell-free systems to study apoptosis. Methods Cell Biol 66:167–185PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2016

Authors and Affiliations

  1. 1.Laboratory of Peptide and Protein ChemistryCentro de Investigación Príncipe FelipeValenciaSpain

Personalised recommendations